- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
AVITA Medical Announces Expanded Compassionate Use of RECELL Device in Life-Threatening Burns
AVITA Medical (ASX:AVH, OTCQX:AVMXY) today announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the U.S. using the RECELL® Autologous Cell Harvesting Device under a Compassionate Use Investigational Device Exemption (IDE) program. As quoted in the press release: The Compassionate …
AVITA Medical (ASX:AVH, OTCQX:AVMXY) today announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be treated in the U.S. using the RECELL® Autologous Cell Harvesting Device under a Compassionate Use Investigational Device Exemption (IDE) program.
As quoted in the press release:
The Compassionate Use program allows the treatment of eligible patients with the RECELL Device in advance of FDA approval. Eligible patients are those who have insufficient healthy skin available for conventional skin grafting treatment of their injuries and whose treating physicians believe there to be no suitable alternative treatment. Currently, 82 patients have already been treated under the Compassionate Use program.
Major U.S. burn centers that have treated patients with the RECELL Device under the Compassionate Use program include Arizona Burn Center at Maricopa Medical Center, Baton Rouge General Hospital, Grady Burn Center – Grady Health System, Maine Medical Center – MaineHealth, Massachusetts General Hospital, MedStar Washington Hospital Center, Regional Medical Center / University of Tennessee, Wake Forest Baptist Medical Center, Walter Reed National Military Medical Center, Riley Hospital for Children (Indianapolis), St. Christopher’s Hospital for Children, Shriners Hospitals for Children – Boston, Sidney & Lois Eskenazi Hospital, U.S. Army Institute for Surgical Research (San Antonio), University of California San Diego Health System, and University of South Alabama.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.